Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 9, 2013, Pages 887-894

  Koh, C ^a   Heller, T ^a   Haynes Williams, V ^a   Hara, K ^a   Zhao, X ^a   Feld, J J ^a   Kleiner, D E ^a   Rotman, Y ^a   Ghany, M G ^a   Liang, T J ^a   Hoofnagle, J H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA2B INTERFERON PLUS RIBAVIRIN; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE ESCALATION; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875863023     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12273     Document Type: Article

References (39)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, MD) 2009; 49: 1335-74.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
3. Williams R,. Global challenges in liver disease. Hepatology (Baltimore, MD) 2006; 44: 521-6.
4. Kim WR,. The burden of hepatitis C in the United States. Hepatology (Baltimore, MD) 2002; 36: S30-4.
5. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
6. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
8. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
9. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
10. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
11. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
12. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
13. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
14. Lindsay KL,. Introduction to therapy of hepatitis C. Hepatology (Baltimore, MD) 2002; 36: S114-20.
15. Swain MG, Lai MY, Shiffman ML, et al,. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.
16. Formann E, Steindl-Munda P, Hofer H, et al,. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23: 507-11.
17. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J,. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology (Baltimore, MD) 2002; 35: 704-8.
18. Camma C, Di BD, Schepis F, et al,. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology (Baltimore, MD) 2004; 39: 333-42.
19. Coverdale SA, Khan MH, Byth K, et al,. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99: 636-44.
20. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM,. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (Baltimore, MD) 2009; 49: 729-38.
21. Hassanein T, Cooksley G, Sulkowski M, et al,. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.
22. Hung CH, Lee CM, Lu SN, et al,. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006; 13: 409-14.
23. Marcellin P, Boyer N, Gervais A, et al,. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.
24. Veldt BJ, Saracco G, Boyer N, et al,. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504-8.
25. John-Baptiste AA, Tomlinson G, Hsu PC, et al,. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.
26. Hoofnagle JH, Mullen KD, Jones DB, et al,. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-8.
27. Di Bisceglie AM, Martin P, Kassianides C, et al,. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
28. Shindo M, Di Bisceglie AM, Cheung L, et al,. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-4.
29. Hoofnagle JH, Ghany MG, Kleiner DE, et al,. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (Baltimore, MD) 2003; 38: 66-74.
30. Feld JJ, Lutchman GA, Heller T, et al,. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139: e4.
31. Rotman Y, Borg BB, Soza A, et al,. Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. Aliment Pharmacol Ther 2010; 31: 1018-27.
32. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
33. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
34. Hara KKC, Sakiani S, Rivera M, Liang TJ, Hoofnagle JH, Heller T,. Important determinants of 5' untranslated region (UTR) in hepatitis C virus (HCV) genotyping: clinical implications for today and the future [abstract]. In: The 62nd Annual Meeting of the America Association for the Study of Liver Diseases 2011; Nov 4-8; San Francisco, CA.
35. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH,. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology (Baltimore, MD) 1998; 28: 1121-7.
36. Bruno S, Stroffolini T, Colombo M, et al,. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (Baltimore, MD) 2007; 45: 579-87.
37. Giannini EG, Basso M, Savarino V, Picciotto A,. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-8.
38. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS,. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-8.
39. Veldt BJ, Heathcote EJ, Wedemeyer H, et al,. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.